Advertisement

Topics

Catabasis Pharmaceuticals Reports Second Quarter 2017 Financial Results and Reviews Business Progress

23:49 EDT 12 Aug 2017 | Biotech-Finances

Thursday, August 10th 2017 at 8:10pm UTC — Favorable Results Seen in 12-week Edasalonexent Phase 2 MoveDMD® Trial in Duchenne Muscular Dystrophy; Phase 3 Clinical Trial Plan Expected Second Half of 2017 — — Preclinical Data Support CAT-5571 as a Potential Treatment to Enhance Host Defenses by Restoring Autophagy in Cystic Fibrosis — CAMBRIDGE, Mass.–(BUSINESS …

Cet article Catabasis Pharmaceuticals Reports Second Quarter 2017 Financial
Results and Reviews Business Progress
est apparu en premier sur EEI-BIOTECHFINANCES.

Original Article: Catabasis Pharmaceuticals Reports Second Quarter 2017 Financial Results and Reviews Business Progress

NEXT ARTICLE

More From BioPortfolio on "Catabasis Pharmaceuticals Reports Second Quarter 2017 Financial Results and Reviews Business Progress"

Quick Search
Advertisement
 

Relevant Topics

Muscular Dystrophy
Muscular dystrophy is a group of degenerative inherited disorders causing muscle weakness and loss of muscle tissue. The different types are Becker muscular dystrophy, Duchenne muscular dystrophy, Emery-Dreifuss muscular dystrophy, Facioscapulohumeral mu...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...